Otonomy: peers
Otonomy beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Otonomy, Seer, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Otonomybase OTIC · 🇺🇸 US Percentile in Healthcare Percentile in USA | PMV Pharmaceuticals, Inc. PMVP · 🇺🇸 US Percentile in Healthcare Percentile in USA | Seer, Inc. SEER · 🇺🇸 US Percentile in Healthcare Percentile in USA | Tonix Pharmaceuticals Holding Corp. TNXP · 🇺🇸 US Percentile in Healthcare Percentile in USA | Vaxart, Inc. VXRT · 🇺🇸 US Percentile in Healthcare Percentile in USA | Rani Therapeutics Holdings, Inc. RANI · 🇺🇸 US Percentile in Healthcare Percentile in USA | LENZ Therapeutics, Inc. LENZ · 🇺🇸 US Percentile in Healthcare Percentile in USA | NRX Pharmaceuticals, Inc. NRXP · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $113 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one4th of 8 | $113 MOct 9, 2026 · Market data5th of 8 | $115 MAug 1, 2026 · Market data3rd of 8 | $111 MOct 20, 2026 · Market data6th of 8 | $117 MOct 22, 2026 · Market data2nd of 8 | $110 MSep 22, 2026 · Market data7th of 8 | $110 MOct 30, 2026 · Market data8th of 8 | $118 MOct 30, 2026 · Market data1st of 8 | $113 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | —— | $17 MFY2025 · SEC3rd of 6 | $13 MFY2025 · SEC4th of 6 | $237 MFY2025 · SEC1st of 6 | $2 MFY2025 · SEC5th of 6 | $19 MFY2025 · SEC2nd of 6 | $1 MFY2025 · SEC6th of 6 | $15 M6 ranked |
| Net income (Higher is better) | —— | $-78 MFY2025 · SEC5th of 7 | $-74 MFY2025 · SEC4th of 7 | $-124 MFY2025 · SEC7th of 7 | $16 MFY2025 · SEC1st of 7 | $-30 MFY2025 · SEC3rd of 7 | $-82 MFY2025 · SEC6th of 7 | $-29 MFY2025 · SEC2nd of 7 | $-74 M7 ranked |
| Employees (Better neither way: ranked highest first) | —— | 35As on 2021 · Profile4th of 5 | 60As on 2019 · Profile3rd of 5 | —— | 15As on 2021 · Profile5th of 5 | 69December 31, 2025 · Profile2nd of 5 | 152December 31, 2025 · Profile1st of 5 | —— | 605 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | ———— | +17.0%FY2025 · SEC4th of 463rd74th | +29.9%FY2025 · SEC3rd of 477th86th | +726.7%FY2025 · SEC1st of 4100th100th | +58.3%FY2025 · SEC2nd of 486th93rd | ———— | ———— | +44.1%4 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | ———— | +2.3%FY2025 · SEConly one with it34th42nd | ———— | ———— | ———— | ———— | ———— | +2.3%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | 51.0%FY2025 · SEC3rd of 438th65th | 49.4%FY2025 · SEC4th of 435th63rd | ———— | ———— | 97.8%FY2025 · SEC1st of 497th99th | 59.0%FY2025 · SEC2nd of 451st73rd | 55.0%4 ranked |
| Operating margin (Higher is better) | ———— | ———— | -470.4%FY2025 · SEC2nd of 47th2nd | -958.8%FY2025 · SEC4th of 40th0th | 7.6%FY2025 · SEC1st of 469th62nd | ———— | -477.4%FY2025 · SEC3rd of 47th2nd | ———— | -473.9%4 ranked |
| Net margin (Higher is better) | ———— | ———— | -443.9%FY2025 · SEC3rd of 47th2nd | -946.0%FY2025 · SEC4th of 40th0th | 6.9%FY2025 · SEC1st of 473rd67th | ———— | -430.2%FY2025 · SEC2nd of 47th2nd | ———— | -437.1%4 ranked |
| Free cash flow margin (Higher is better) | ———— | ———— | -278.9%FY2025 · SEC2nd of 412th3rd | -787.3%FY2025 · SEC4th of 42nd1st | 3.2%FY2025 · SEC1st of 458th46th | ———— | -366.7%FY2025 · SEC3rd of 410th2nd | ———— | -322.8%4 ranked |
| Return on equity (Higher is better) | ———— | -55.4%FY2025 · SEC4th of 640th17th | -25.1%FY2025 · SEC2nd of 658th26th | -64.5%FY2025 · SEC5th of 636th15th | 22.3%FY2025 · SEC1st of 692nd87th | -169.5%FY2025 · SEC6th of 613th6th | -33.6%FY2025 · SEC3rd of 652nd22nd | ———— | -44.5%6 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | 4.0×price Oct 22, 2026 · Market dataonly one with it5th3rd | ———— | ———— | ———— | 4.0×— |
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | 8.2׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 8.5×price Oct 20, 2026 · Market data3rd of 571st87th | 0.7×price Oct 22, 2026 · Market data5th of 511th20th | 67.6×price Sep 22, 2026 · Market data2nd of 593rd97th | 5.7×price Oct 30, 2026 · Market data4th of 560th80th | 96.7×price Oct 30, 2026 · Market data1st of 595th98th | 8.5×5 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | 1.1×price Oct 9, 2026 · Market data3rd of 520th22nd | 0.4׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 0.5×price Oct 20, 2026 · Market data4th of 56th6th | 1.3×price Oct 22, 2026 · Market data2nd of 526th32nd | 3.3×price Sep 22, 2026 · Market data1st of 554th65th | 0.4×price Oct 30, 2026 · Market data5th of 54th4th | ———— | 1.1×5 ranked |
| Free cash flow yield (Higher is better) | ———— | -65.4%price Oct 9, 2026 · Market data5th of 614th5th | -40.2%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | -92.7%price Oct 20, 2026 · Market data6th of 68th3rd | 6.5%price Oct 22, 2026 · Market data1st of 691st74th | -17.1%price Sep 22, 2026 · Market data3rd of 635th16th | -63.8%price Oct 30, 2026 · Market data4th of 614th6th | -9.0%price Oct 30, 2026 · Market data2nd of 645th22nd | -40.4%6 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | ———— | ———— | 0.0×FY2025 · SEConly one with it5th3rd | ———— | ———— | 0.0×— |
| Interest cover (Higher is better) | ———— | ———— | ———— | ———— | ———— | -13.3×FY2025 · SEConly one with it40th20th | ———— | ———— | -13.3×— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 3 of 12FY2025 · Scorecard5th of 7 | 4 of 14FY2025 · Scorecard3rd of 7 | 5 of 17FY2025 · Scorecard2nd of 7 | 13 of 18FY2025 · Scorecard1st of 7 | 4 of 18FY2025 · Scorecard6th of 7 | 4 of 15FY2025 · Scorecard4th of 7 | 1 of 11FY2025 · Scorecard7th of 7 | 27% passed7 ranked |
| Valuation checks (Higher is better) | —— | 1 of 4FY2025 · Scorecard4th of 6 | —— | 2 of 5FY2025 · Scorecard2nd of 6 | 5 of 5FY2025 · Scorecard1st of 6 | 0 of 5FY2025 · Scorecard5th of 6 | 2 of 5FY2025 · Scorecard2nd of 6 | 0 of 5FY2025 · Scorecard5th of 6 | 33% passed6 ranked |
| Growth checks (Higher is better) | —— | 0 of 2FY2025 · Scorecard6th of 7 | 2 of 5FY2025 · Scorecard3rd of 7 | 1 of 3FY2025 · Scorecard4th of 7 | 3 of 4FY2025 · Scorecard2nd of 7 | 1 of 3FY2025 · Scorecard4th of 7 | 0 of 2FY2025 · Scorecard6th of 7 | 1 of 1FY2025 · Scorecard1st of 7 | 33% passed7 ranked |
| Profitability checks (Higher is better) | —— | 0 of 3FY2025 · Scorecard3rd of 7 | 1 of 5FY2025 · Scorecard2nd of 7 | 0 of 4FY2025 · Scorecard3rd of 7 | 4 of 5FY2025 · Scorecard1st of 7 | 0 of 3FY2025 · Scorecard3rd of 7 | 0 of 4FY2025 · Scorecard3rd of 7 | 0 of 2FY2025 · Scorecard3rd of 7 | 0% passed7 ranked |
| Financial health checks (Higher is better) | —— | 1 of 2FY2025 · Scorecard2nd of 7 | 1 of 3FY2025 · Scorecard4th of 7 | 1 of 3FY2025 · Scorecard4th of 7 | 1 of 3FY2025 · Scorecard4th of 7 | 3 of 6FY2025 · Scorecard2nd of 7 | 2 of 3FY2025 · Scorecard1st of 7 | 0 of 3FY2025 · Scorecard7th of 7 | 33% passed7 ranked |
| Shareholder returns checks (Higher is better) | —— | 1 of 1FY2025 · Scorecard1st of 6 | 0 of 1FY2025 · Scorecard3rd of 6 | 1 of 2FY2025 · Scorecard2nd of 6 | 0 of 1FY2025 · Scorecard3rd of 6 | 0 of 1FY2025 · Scorecard3rd of 6 | 0 of 1FY2025 · Scorecard3rd of 6 | —— | 0% passed6 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | 74.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 38.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7 | 51.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 0.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 33.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | 97.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 32.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7 | 38.5%7 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | 652026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | 682026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 1132026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 52026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 682026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 1382026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 502026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7 | 687 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | -4.6 pp2026-Q2 against 2026-Q1 · 13F6th of 6 | -0.6 pp2026-Q2 against 2026-Q1 · 13F5th of 6 | +18.3 pp2026-Q2 against 2026-Q1 · 13F1st of 6 | +0.0 pp2026-Q2 against 2026-Q1 · 13F4th of 6 | —— | +4.8 pp2026-Q2 against 2026-Q1 · 13F3rd of 6 | +8.3 pp2026-Q2 against 2026-Q1 · 13F2nd of 6 | +2.4 pp6 ranked |
| Dividends | |||||||||
| Shareholder yield (Higher is better) | ———— | ———— | ———— | 12.4%FY2025 · SEConly one with it94th92nd | ———— | ———— | ———— | ———— | 12.4%— |
| Dividend per share (Better neither way: ranked highest first) | —— | —— | $0.00FY2025 · SEConly one with it | —— | —— | —— | —— | —— | $0.00— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Otonomy: How market caps are worked out; PMV Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Seer, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Tonix Pharmaceuticals Holding Corp.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Vaxart, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Rani Therapeutics Holdings, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; LENZ Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; NRX Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Otonomy | — | — | — |
| PMV Pharmaceuticals, Inc. | — | — | — |
| Seer, Inc. | -470.4%FY2025 | 7th percentile in Healthcaremedian -7.7%, 674 companies | 2nd percentile in USAmedian 3.5%, 2,594 companies |
| Tonix Pharmaceuticals Holding Corp. | -958.8%FY2025 | 0th percentile in Healthcaremedian -7.7%, 674 companies | 0th percentile in USAmedian 3.5%, 2,594 companies |
| Vaxart, Inc. | 7.6%FY2025 | 69th percentile in Healthcaremedian -7.7%, 674 companies | 62nd percentile in USAmedian 3.5%, 2,594 companies |
| Rani Therapeutics Holdings, Inc. | — | — | — |
| LENZ Therapeutics, Inc. | -477.4%FY2025 | 7th percentile in Healthcaremedian -7.7%, 674 companies | 2nd percentile in USAmedian 3.5%, 2,594 companies |
| NRX Pharmaceuticals, Inc. | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Otonomy | PMV Pharmaceuticals, Inc. | Seer, Inc. | Tonix Pharmaceuticals Holding Corp. | Vaxart, Inc. | Rani Therapeutics Holdings, Inc. | LENZ Therapeutics, Inc. | NRX Pharmaceuticals, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | $17 MSEC3rd | $13 MSEC4th | $237 MSEC1st | $2 MSEC5th | $19 MSEC2nd | $1 MSEC6th |
| 2024 | — | — | $14 MSEC2nd | $10 MSEC3rd | $29 MSEC1st | $1 MSEC4th | — | — |
| 2023 | — | — | $17 MSEC1st | $8 MSEC2nd | $7 MSEC3rd | — | — | — |
| 2022 | — | — | $15 MSEC1st | — | $0 MSEC2nd | — | — | — |
| 2021 | — | — | $7 MSEC1st | — | $1 MSEC3rd | $3 MSEC2nd | — | — |
| 2020 | — | — | $1 MSEC2nd | — | $4 MSEC1st | $0 MSEC3rd | — | — |
| 2019 | — | — | — | — | $10 MSEC | — | — | — |
| 2018 | — | — | — | — | $4 MSEC | — | — | — |
| 2017 | — | — | — | — | $9 MSEC | — | — | — |
| 2016 | — | — | — | — | $9 MSEC | — | — | — |
| 2015 | — | — | — | — | $25 MSEC | — | — | — |
| 2014 | — | — | — | — | $69 MSEC | — | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Otonomy#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- PMV Pharmaceuticals, Inc.PMVP · 🇺🇸 USASame industry: Biotechnology · Similar size: $113 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $113 M (Oct 9, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Seer, Inc.SEER · 🇺🇸 USASame industry: Biotechnology · Similar size: $115 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $115 M (Aug 1, 2026) · revenue $17 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Tonix Pharmaceuticals Holding Corp.TNXP · 🇺🇸 USASame industry: Biotechnology · Similar size: $111 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $111 M (Oct 20, 2026) · revenue $13 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Vaxart, Inc.VXRT · 🇺🇸 USASame industry: Biotechnology · Similar size: $117 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $117 M (Oct 22, 2026) · revenue $237 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Rani Therapeutics Holdings, Inc.RANI · 🇺🇸 USASame industry: Biotechnology · Similar size: $110 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $110 M (Sep 22, 2026) · revenue $2 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- LENZ Therapeutics, Inc.LENZ · 🇺🇸 USASame industry: Biotechnology · Similar size: $110 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $110 M (Oct 30, 2026) · revenue $19 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- NRX Pharmaceuticals, Inc.NRXP · 🇺🇸 USASame industry: Biotechnology · Similar size: $118 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $118 M (Oct 30, 2026) · revenue $1 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Black Diamond Therapeutics, Inc.BDTX · 🇺🇸 USASame industry: Biotechnology · Similar size: $108 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $108 M (Oct 26, 2026) · revenue $70 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Immunic, Inc.IMUX · 🇺🇸 USASame industry: Biotechnology · Similar size: $121 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $121 M (Oct 28, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Outlook Therapeutics, Inc.OTLK · 🇺🇸 USASame industry: Biotechnology · Similar size: $119 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $119 M (Oct 30, 2026) · revenue $1 M (year to September 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- OnKure Therapeutics, Inc.OKUR · 🇺🇸 USASame industry: Biotechnology · Similar size: $107 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $107 M (Oct 29, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Foghorn Therapeutics Inc.FHTX · 🇺🇸 USASame industry: Biotechnology · Similar size: $123 M market cap against $113 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $123 M (Oct 28, 2026) · revenue $31 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.